Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy

Sujit Sheth, Carrie Ruzal-Shapiro, Anne Hurlet-Jensen, Sergio Piomelli, Walter E. Berdon

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Pulmonary disease, including thromboembolic problems, accounts for a large portion of the morbidity of sickle cell disease. Chronic transfusion therapy is now a part of long-term treatment of sickle cell patients with stroke and chest syndrome. The resultant iron overload must be treated with chelation therapy using deferoxamine. Poor compliance with subcutaneous chelation therapy has necessitated intravenous deferoxamine treatment. We describe two patients with sickle cell disease on such a regimen, who became hypoxic as a result of pulmonary thromboembolism, secondary to venous thrombophlebitis. The thrombophlebitis and subsequent pulmonary embolism probably reflect the hypercoagulable state seen in sickle cell and are not due to the deferoxamine therapy.

Original languageEnglish
Pages (from-to)926-928
Number of pages3
JournalPediatric Radiology
Volume27
Issue number12
DOIs
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Dive into the research topics of 'Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy'. Together they form a unique fingerprint.

Cite this